Human Leukemia Growth Inhibition by a Novel Retinoid
新型类维生素A抑制人类白血病生长
基本信息
- 批准号:7237940
- 负责人:
- 金额:$ 45.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-07-01 至 2009-04-30
- 项目状态:已结题
- 来源:
- 关键词:3-chlorophenol4-bromophenolA549AHPNAcidsAcridine OrangeAcridinesActinsAcuteAcute Lymphocytic LeukemiaAcute Myelocytic LeukemiaAcute Promyelocytic LeukemiaAcute leukemiaAdoptedAdriamycin PFSAdult Acute Lymphocytic LeukemiaAdverse effectsAffectAffinityAgarAgeAge-YearsAgonistAldehydesAlkaline PhosphataseAlkylationAlkynesAmericanAminesAnalysis of VarianceAnimalsAntibodiesAntigensAntineoplastic AgentsAntsAnusApoptosisApoptosis PromoterApoptosis RegulatorApoptoticAppendixAra-CAssesAutoradiographyAzidesB-LymphocytesBCL1 OncogeneBacteriaBaltimoreBedsBexaroteneBindingBinding SitesBiohazardous SubstanceBiologicalBiological AssayBiological MarkersBiopsyBiteBlast CellBlast PhaseBlood CirculationBody WeightBody Weight decreasedBone MarrowBone Marrow TransplantationBoranesBoronic AcidsBreastBreast CarcinomaBritishBromidesBuffersCD3 AntigensCD34 geneCDKN1A geneCanadaCarbon DioxideCarboxy-LyasesCarboxylic AcidsCell CycleCell Cycle ArrestCell DeathCell LineCell NucleusCellsCessation of lifeChemistryChemotherapy-Oncologic ProcedureChimeric ProteinsChloride IonChloridesChromosomes, Human, Pair 9ChronicChronic Lymphocytic LeukemiaChronic Myeloid LeukemiaClassClassificationClinicClinicalCodon NucleotidesCollaborationsColorCompetitive BindingComplement component C1sComplement component C4aCompomersConditionConsensusConsensus SequenceCountCouplingCp CAPCritical PathwaysCytarabineCytogeneticsCytolysisCytoplasmCytosineD CellsDNADactinomycinDataDatabasesDaunorubicinDetectionDevelopmentDiagnosisDialysis procedureDiseaseDisease ProgressionDisease remissionDisease-Free SurvivalDissociationDockingDominant-Negative MutationDoseDown-RegulationDoxorubicinDrug vehicleE2F1 geneEatingEelsElectronsElementsEmbryoEngraftmentEnvironmentEnzyme-Linked Immunosorbent AssayEpidermisEpitopesEquilibriumEthersEthyl EtherEtiologyEtoposideEventExperimental DesignsExposure toEyeFCGR3B geneFailureFamilyFamily memberFelis catusFemaleFibroblastsFicollFigs - dietaryFlow CytometryFoodFrequenciesFrightFutureGasesGelGenbankGene ExpressionGene Expression RegulationGene TargetingGenerationsGenesGenetic TranscriptionGenomicsGroupingGrowthGrowth FactorGuidelinesHL-60 CellsHamstersHarvestHelix (Snails)HematopoieticHepatocyteHeterogeneous-Nuclear RibonucleoproteinsHourHumanHuman GenomeHydrogenationHypaqueImatinib mesylateImmunophenotypingImplantIn VitroIn complete remissionInbred C3H MiceIncubatedIndividualIndolesInduction of ApoptosisInhibitory Concentration 50Injection of therapeutic agentInvestigationIodidesIonsIsomerismIsopropyl ThiogalactosideKaryotypeKetonesKnock-outLNCaPLabelLaboratoriesLasersLateralLearningLegal patentLettersLeukemic CellLifeLigand Binding DomainLigandsLightLiteratureLocationLongevityLuciferasesLyeLymphoblastic LeukemiaMAPK14 geneMCF7 cellMagnetic Resonance ImagingMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of lungMann-Whitney U TestManuscriptsMapsMarrowMaximum Tolerated DoseMeasuresMediatingMediator of activation proteinMembraneMessenger RNAMethodologyMethodsMinorMinorityModalityModelingModificationMolecularMolecular ConformationMorphologyMountain LionMusMutateMutationMyelogenousMyeloid LeukemiaN-formylpiperidineNF-kappa BNFKB Activation PathwayNail plateNamesNaphthaleneNaphthalenesNational Cancer InstituteNeckNeuro-Oncological Ventral Antigen 2Non obeseNuclearNuclear ReceptorsNude MiceNumbersObject AttachmentOncogenesOrgan Culture TechniquesPCNA genePTPRC genePathologyPathway interactionsPatientsPeptidesPharmaceutical PreparationsPhasePhase III Clinical TrialsPhenolsPhenotypePhosphotransferasesPhysical DialysisPhysiologic pulsePlasmidsPlayPolymerase Chain ReactionPongidaePopulationPositioning AttributePost-Translational RegulationPrincipal InvestigatorProceduresProcessProductionPrognostic MarkerProliferatingProstateProteasome InhibitorProtein OverexpressionProtein Tyrosine KinaseProteinsProteolysisProtocols documentationProtonsPtosisPublicationsPulse takingPurposeQuantitative Structure-Activity RelationshipRHOA geneRXRRadioRangeRateRattusReactionReactive Oxygen SpeciesRefluxRefractoryRegulationRelapseRelative (related person)ReporterReportingRepressionResearchResearch InstituteResearch PersonnelResistanceRetinoid ReceptorRetinoidsRetroviral VectorRetroviridaeReverse Transcriptase Polymerase Chain ReactionRoleRouteRunningSCID MiceSM 22 muscle proteinSamplingScheduleSchemeScoreSecondary toSerineSerumShockSignal PathwaySignal TransductionSinusSiteSodiumSodium AzideSodium ChlorideSourceSpecimenSpleenStandards of Weights and MeasuresStem cellsSterilityStimulusStructureStructure of thyroid parafollicular cellSurfaceSurface AntigensSystemT-LymphocyteTMEDATNFRSF10A geneTNFRSF10B geneTNFRSF5 geneTailTarsTeaTechniquesTestingTheftTherapeuticTherapeutic AgentsTherapeutic IndexTimeTopoisomeraseTopoisomerase IITorsionToxic effectToxicologyTracheaTrainingTranscriptional ActivationTransgenic MiceTranslationsTransplantationTreatment EfficacyTreatment ProtocolsTretinoinTumor BankTumor Necrosis Factor-alphaTumor Necrosis FactorsTumor PromotersTyrosine Kinase InhibitorUnited States National Institutes of HealthUniversitiesUntranslated RegionsUp-RegulationUpper armVeinsVertebral columnVertebratesViralVitamin AWeekWeight GainWestern BlottingWithdrawalWorkalanine aminopeptidaseanalogbacterial lysatebasebeta Globinboronic acidc-myc Genescancer cellcell growthcell growth regulationcell killingcell typechemotherapeutic agentchemotherapychlorinationcomputer studiesconformerdaydesigndetectordiabeticdimerdosagedrug efficacyear helixelectron donorexperienceexpression vectorfallsfootfusion genegel electrophoresisgenetic regulatory proteinhelenalinhnRNP A1human TNF proteinhuman stem cellsimprovedin vivoin vivo Modelindexingindoleinhibitor/antagonistirradiationkeratinizationkillingsleukemiamalignant breast neoplasmmelanomamembermessenger ribonucleoproteinmethyl groupmolecular dynamicsmouse modelmulticatalytic endopeptidase complexmutantn-butyllithiumnext generationnitrenenovelolder patientoncologyoncoprotein p21outcome forecastoxazolidinep65peripheral bloodpharmacophorepol genespre-clinicalpreventprogramspromoterprotein Kprotein functionreceptorreceptor bindingresearch studyresponsescaffoldsizesodium sulfidestannanestemtitanium carbidetranscription factortumorvector
项目摘要
DESCRIPTION (provided by applicant): 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN/CD437) belongs to a class of adamantyl retinoids (AR) that induce apoptosis through as yet undefined mechanism(s). We have now identified an AHPN analog 4-[3-(1-adamanyly)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-CI-AHPC), which binds to, but does not activate, the retinoic acid nuclear receptors. 3-C1-AHPC displays decreased toxicity compared to AHPN but continues to display high efficacy in inhibiting human acute myelogenous leukemia (AML) cell growth in vitro and mouse AML cells in vivo. In addition, we have found that 3-C1-AHPC induces the expression of a novel protein termed CARP-1. We recently identified CARP-1 as an important regulator of apoptosis by the ARs. Hypothesis: In this proposal we hypothesize that 3-C1-AHPC and newly synthesized analogs are highly active in inhibiting the growth of human primary AML cells in NOD-SCID mice and thus represent potential therapeutic agents in the treatment of AML. In addition, we also hypothesize that 3-CL-AHPC/analog apoptosis signaling is through its activation of the important transcriptional regulator, NFkB, and CARP-l-mediated pathways. Our hypothesis is based on the following observations. 1) 3-CI-AHPC inhibits the growth of AML cells in a syngeneic mouse model, patient derived AML cells, and human AML cell lines. 2) Inhibition of NFkB activation or inhibition of CARP-1 expression blocks 3-C1-AHPC-mediated apoptosis. We will confirm our hypothesis by conducting the following specific aims. Aim 1: Synthesize new analogs of 3-C1-AHPC. Aim 2: Demonstrate that 3-C1-AHPC and its analogs inhibit in vivo growth of human primary AML cells in NOD-SCID mice and display reduced toxicity. Aim 3: Delineate the mechanism(s) by which 3-CI-AHPC enhances CARP-1 expression and CARP-l-dependent reduced topoisomerase lIa levels. Aim 4: Delineate the pathway by which 3-C1-AHPC activates NFkB and its role in apoptosis induction.
描述(由申请人提供):6- [3-(1-亚氨烷)-4-羟基苯基] -2-萘甲苯乙烯羧酸(AHPN/CD437)属于一类adamantyl andinoi-Otiniofics(AR),通过尚未确定的机制诱导凋亡。现在,我们已经鉴定出AHPN类似物4- [3-(1-二木)-4-羟基苯基] -3-氯环酸(3-CI-AHPC),该核酸(3-CI-AHPC)与视β核受体结合但不激活。与AHPN相比,3-C1-AHPC的毒性降低,但在抑制人体内抑制人类急性粒细胞性白血病(AML)细胞生长方面的效力很高。此外,我们发现3-C1-AHPC诱导了称为鲤鱼1的新型蛋白质的表达。我们最近将Carp-1确定为ARS凋亡的重要调节剂。假设:在此提案中,我们假设3-C1-AHPC和新合成的类似物在抑制NOD-SCID小鼠中人类原代AML细胞的生长方面高度活跃,因此代表了AML治疗中潜在的治疗剂。此外,我们还假设3-CL-AHPC/模拟凋亡信号通过其激活重要的转录调节剂,NFKB和Carp-L介导的途径。我们的假设基于以下观察结果。 1)3-CI-AHPC抑制合成小鼠模型,患者衍生的AML细胞和人AML细胞系中AML细胞的生长。 2)抑制NFKB激活或抑制鲤鱼1表达阻断3-C1-AHPC介导的细胞凋亡。我们将通过执行以下特定目标来确认我们的假设。目标1:合成3-C1-AHPC的新类似物。 AIM 2:证明3-C1-AHPC及其类似物抑制了点数scID小鼠中人类原代AML细胞的体内生长,并显示出降低的毒性。 AIM 3:描述3-CI-AHPC增强Carp-1表达和鲤鱼L依赖性降低拓扑异构酶LIA水平的机制。 AIM 4:描述3-C1-AHPC激活NFKB及其在凋亡诱导中的作用的途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSEPH A FONTANA其他文献
JOSEPH A FONTANA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSEPH A FONTANA', 18)}}的其他基金
Human Leukemia Growth Inhibition by a Novel Retinoid
新型类维生素A抑制人类白血病生长
- 批准号:
7087066 - 财政年份:2004
- 资助金额:
$ 45.86万 - 项目类别:
Human Leukemia Growth Inhibition by a Novel Retinoid
新型类维生素A抑制人类白血病生长
- 批准号:
6815356 - 财政年份:2004
- 资助金额:
$ 45.86万 - 项目类别:
Human Leukemia Growth Inhibition by a Novel Retinoid
新型类维生素A抑制人类白血病生长
- 批准号:
7409181 - 财政年份:2004
- 资助金额:
$ 45.86万 - 项目类别:
Human Leukemia Growth Inhibition by a Novel Retinoid
新型类维生素A抑制人类白血病生长
- 批准号:
6914222 - 财政年份:2004
- 资助金额:
$ 45.86万 - 项目类别:
相似海外基金
Human Leukemia Growth Inhibition by a Novel Retinoid
新型类维生素A抑制人类白血病生长
- 批准号:
7409181 - 财政年份:2004
- 资助金额:
$ 45.86万 - 项目类别: